Questions // straight answers
Ipamorelin FAQ
The questions people actually ask, answered without the sales pitch. Every number cited.
Is ipamorelin FDA approved?
No. Ipamorelin has never been approved as a drug by the FDA or any other regulator [13]. It was investigated for postoperative ileus, but that single Phase 2 trial missed its primary endpoint and development stopped [3]. A 2026 sports-medicine review groups it among unapproved peptides marketed to patients, noting favorable animal signals but scarce rigorous human safety data [13]. It's sold only as a research chemical.
Is ipamorelin legal?
It occupies a gray zone, not a clean "yes." Ipamorelin isn't a controlled substance, but it's not an approved drug either — it's sold "for research use only," not for human use [13]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at an October 2024 PCAC meeting, narrowing legal compounding access [13]. Marketing or using it as a treatment runs ahead of its legal standing.
Is ipamorelin banned by WADA?
Yes. Ipamorelin and other growth hormone secretagogues are prohibited at all times under the WADA Prohibited List, category S2 (peptide hormones, growth factors, related substances and mimetics) [14]. It's not a competition-only ban, and accredited anti-doping labs have established urine-detection methods for it [14]. For any tested athlete, the answer is unambiguous: prohibited.
Why did the FDA restrict ipamorelin compounding?
In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list after the nominator withdrew it in September 2024, and reviewed both the acetate and free base at the October 29, 2024 PCAC meeting [13]. The backdrop: no approved indication, a failed Phase 2 trial [3], and class-level safety questions. The result is that compounding-pharmacy access narrowed — ipamorelin is not an approved bulk substance for compounding.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and the first selective growth hormone secretagogue [1]. It activates the ghrelin / GHS-R1a receptor to release a GH pulse, and its defining trait is selectivity — in rats and swine it released GH potently (swine ED50 = 2.3 nmol/kg vs 3.9 for GHRP-6) without raising ACTH or cortisol even far above its GH threshold [1]. It's a research peptide, not an approved drug.
What does ipamorelin do for you?
In studies, ipamorelin triggers a discrete pulse of growth hormone by activating the ghrelin receptor on the pituitary [1]. That's the proven pharmacology. Beyond it, animal work shows dose-dependent bone growth in rats [4] and blunted chemotherapy weight loss in ferrets [5]. What it does "for you" specifically is unproven — its only human efficacy trial failed [3], and the wellness claims rest on mechanism and anecdote, not controlled human outcomes.
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic, five-amino-acid chain engineered to mimic ghrelin at the GHS-R1a receptor [1]. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2; a non-natural amino acid (Aib) and two D-form residues make it resistant to enzymatic breakdown [1]. It weighs about 712 daltons and was derived from the earlier peptide GHRP-1. The body doesn't make it — it's a lab-built ghrelin mimetic.
What are the risks of ipamorelin?
The biggest risk is the unknown: no long-term human safety database exists, and the dominant real-world route (subcutaneous self-injection) has no published human safety data [3]. Class-level concerns include a cardiotoxicity signal seen with a related GHS-R1a agonist in rats [6] and theoretical GH/IGF-1 worries around glucose and proliferative conditions [1]. Research-grade material from unregulated suppliers also carries unverified purity [3]. The detailed, cited cautions are on the Ipamorelin effects page.
Does ipamorelin reduce belly fat?
There's no controlled human evidence that it does. The relevant data is animal: in a 2024 ferret study, ipamorelin (1 to 3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% in the delayed phase, with no anti-emetic effect [5]. That's about preserving weight during chemotherapy, not trimming belly fat in healthy people. Community reports of a gradual leaner look are anecdotal and confounded by diet and training — not a clinical finding.
What are the downsides of ipamorelin?
Start with efficacy: its only published human trial failed its primary endpoint [3]. Then the unknowns: no Phase 3, no long-term human safety data, and no safety characterization for the self-injection route most people use [3]. Add a class-level cardiotoxicity signal from a related agonist [6] and unverified purity in gray-market material [3]. Community-reported downsides — flushing, tingling, water retention, appetite spikes — are detailed and labeled anecdotal on the Ipamorelin effects page.
Why is ipamorelin being discontinued?
It was never an approved product, so "discontinued" really refers to its clinical development stopping and its 2024 regulatory tightening. The postoperative-ileus program ended after its Phase 2 trial missed the primary endpoint [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A list and reviewed it at the October 2024 PCAC meeting, narrowing compounding access [13]. So the trajectory is failed-efficacy plus tightened access, not the withdrawal of an approved medicine.
What does CJC-1295 and ipamorelin do?
Used together, they aim to produce a larger GH pulse than either alone by hitting two different receptors — CJC-1295 the GHRH receptor, ipamorelin the ghrelin receptor [1]. The rationale is class-level synergy: chronic GHRP or GHRH dosing converted an additive GH response into a synergistic one in adults [9]. But the combination itself has never been tested in a controlled trial for any outcome [3], so its real-world results are unproven.
Does ipamorelin increase IGF-1?
Not consistently in short studies. In adult rats dosed for 15 days, ipamorelin produced dose-dependent bone growth with no measurable change in total IGF-1 [4] — suggesting a partly local, GH-pulse-driven effect rather than a systemic IGF-1 surge. IGF-1 is the liver-made messenger that carries many GH effects, and longer or higher-dose protocols may differ, but the short-term rodent data did not show an IGF-1 rise [4].
How does CJC-1295 ipamorelin work?
CJC-1295 (a GHRH analog) raises the pituitary's GH-releasing drive through the GHRH receptor; ipamorelin (a GHRP) adds a sharp GH pulse through the ghrelin / GHS-R1a receptor without raising cortisol [1]. Because the two receptors are distinct, the effects are complementary — the basis for pairing them. Class-level studies show GHRP plus GHRH can be synergistic rather than merely additive [9][11], though no trial has tested this specific combination [3].
How much CJC-1295 ipamorelin should I take?
There's no legitimate dose to give. Neither ipamorelin nor the CJC-1295 + ipamorelin combination has an approved human dose, and no controlled trial of the combination established one for any outcome [3]. The amounts in community protocols are self-experimentation with no peer-reviewed human dosing basis [3]. This site reports what studies administered (mostly IV, in animals or surgical patients) and won't reproduce a forum protocol as if it were medicine.
Does CJC-1295 ipamorelin work?
For releasing GH, the mechanism is established and the class-level synergy is documented [9][10]. For any clinical outcome — fat loss, muscle, anti-aging — there's no controlled human trial of the combination proving it [3], and ipamorelin's solo human trial failed [3]. So it reliably does the pharmacological thing (a GH pulse) without trial-grade proof of the body-composition results it's marketed for.
How to reconstitute CJC-1295 ipamorelin 5mg?
As lyophilized (freeze-dried) peptides, these are supplied as powder and reconstituted with bacteriostatic water for research handling; as peptides they degrade with heat and freeze-thaw, so reconstituted research solutions are typically refrigerated [2]. That's a general handling note from the research-supply literature, not a human preparation instruction or a measured-volume recipe — there's no approved 5mg human product to prepare, and the combination has no controlled human dosing basis [3].
How long does ipamorelin stay in your system?
In healthy men, ipamorelin's terminal half-life is about 2 hours by the IV route, with clearance of 0.078 L/h/kg [2]. The GH pulse it triggers peaks around 40 minutes after dosing and then subsides — a single discrete pulse, not a sustained elevation [2]. So the peptide itself clears within hours, though detection windows for anti-doping purposes are a separate question governed by accredited lab methods [14].
Does ipamorelin make you hungry?
It can, by mechanism. Ipamorelin acts on the ghrelin receptor — ghrelin being the body's "hunger hormone" — so an uptick in appetite after dosing is plausible, and some users report exactly that [1]. Community accounts describe it as milder than with GHRP-6 but still real for some people watching their intake. There's no controlled human appetite study for ipamorelin specifically; the appetite reports are anecdotal.
Will I gain weight on ipamorelin?
There's no controlled human evidence either way. Animal data point both directions depending on context: ipamorelin blunted weight loss during chemotherapy in ferrets [5], and class-level ghrelin-agonist effects include appetite stimulation [1]. Any weight change in real-world use is unmeasured, confounded by diet and training, and not a clinical finding. Its only human efficacy trial wasn't about weight and failed its own endpoint anyway [3].
Does ipamorelin increase appetite?
Plausibly, through its mechanism. As a ghrelin / GHS-R1a agonist, ipamorelin acts on the same receptor the hunger hormone ghrelin uses, and ghrelin-receptor agonists activate appetite circuits [1]. Some users report increased hunger after injecting, described as milder than with GHRP-6 [1]. No controlled human appetite trial exists for ipamorelin specifically, so this is mechanism plus anecdote, not a measured clinical outcome.
What does ipamorelin peptide do?
Ipamorelin peptide activates the ghrelin / GHS-R1a receptor on the pituitary to release a discrete pulse of growth hormone, doing so selectively — without raising cortisol or prolactin, its signature trait [1]. In animals it has produced dose-dependent bone growth [4] and blunted chemotherapy-related weight loss [5]. In its one human efficacy trial it failed its primary endpoint [3]. The proven action is the GH pulse; the marketed benefits remain unproven in controlled human studies.